AP2000002002A0 - Method of treatment. - Google Patents
Method of treatment.Info
- Publication number
- AP2000002002A0 AP2000002002A0 APAP/P/2000/002002A AP2000002002A AP2000002002A0 AP 2000002002 A0 AP2000002002 A0 AP 2000002002A0 AP 2000002002 A AP2000002002 A AP 2000002002A AP 2000002002 A0 AP2000002002 A0 AP 2000002002A0
- Authority
- AP
- ARIPO
- Prior art keywords
- treatment
- smoking
- paroxetine
- solvate
- human
- Prior art date
Links
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 abstract 1
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 abstract 1
- 231100000252 nontoxic Toxicity 0.000 abstract 1
- 230000003000 nontoxic effect Effects 0.000 abstract 1
- 229960002296 paroxetine Drugs 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000005586 smoking cessation Effects 0.000 abstract 1
- 230000000391 smoking effect Effects 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9812941.4A GB9812941D0 (en) | 1998-06-16 | 1998-06-16 | Method of treatment |
| PCT/US1999/013623 WO1999065491A1 (en) | 1998-06-16 | 1999-06-16 | Method of treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AP2000002002A0 true AP2000002002A0 (en) | 2000-12-31 |
Family
ID=10833832
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| APAP/P/2000/002002A AP2000002002A0 (en) | 1998-06-16 | 1999-06-16 | Method of treatment. |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP1087766A4 (cs) |
| JP (1) | JP2002518330A (cs) |
| KR (1) | KR20010052895A (cs) |
| CN (1) | CN1305379A (cs) |
| AP (1) | AP2000002002A0 (cs) |
| AU (1) | AU740749B2 (cs) |
| BG (1) | BG105127A (cs) |
| BR (1) | BR9911150A (cs) |
| CA (1) | CA2335236A1 (cs) |
| CZ (1) | CZ20004698A3 (cs) |
| EA (1) | EA003584B1 (cs) |
| GB (1) | GB9812941D0 (cs) |
| HU (1) | HUP0102507A3 (cs) |
| IL (1) | IL139943A0 (cs) |
| NO (1) | NO20006383L (cs) |
| NZ (1) | NZ508532A (cs) |
| PL (1) | PL345261A1 (cs) |
| SK (1) | SK19192000A3 (cs) |
| WO (1) | WO1999065491A1 (cs) |
| ZA (1) | ZA200007396B (cs) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1313474A2 (en) * | 2000-08-28 | 2003-05-28 | Synthon B.V. | Paroxetine compositions and processes for making the same |
| US7396542B2 (en) * | 2001-12-28 | 2008-07-08 | Teva Pharmaceutical Industries Ltd. | Stable pharmaceutical formulation of paroxetine hydrochloride anhydrous and a process for preparation thereof |
| US20060039975A1 (en) * | 2004-08-20 | 2006-02-23 | Zalman Vilkov | Paroxetine formulations |
| FR2926221A1 (fr) * | 2008-01-14 | 2009-07-17 | Tassin Thomas | Compositions permettant la reproduction artificielle des conditions pharmacologiques de la dependance aux drogues addictives telles que opiaces, psychostimulants, tabac et alcool, par la combinaison de nicotine et d'un ligand. |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0223403B1 (en) * | 1985-10-25 | 1993-08-04 | Beecham Group Plc | Piperidine derivative, its preparation, and its use as medicament |
| JPH06502854A (ja) * | 1990-11-24 | 1994-03-31 | ビーチャム・グループ・パブリック・リミテッド・カンパニー | 老年痴呆、過食症、片頭痛または食欲不振の治療用のパロキセチンの使用 |
| AR001982A1 (es) * | 1995-02-06 | 1998-01-07 | Smithkline Beecham Plc | Clorhidrato de paroxetina anhidratado, y procedimiento para su preparacion |
| GB9605828D0 (en) * | 1996-03-20 | 1996-05-22 | Smithkline Beecham Plc | Treatment method |
-
1998
- 1998-06-16 GB GBGB9812941.4A patent/GB9812941D0/en not_active Ceased
-
1999
- 1999-06-16 JP JP2000554371A patent/JP2002518330A/ja not_active Withdrawn
- 1999-06-16 KR KR1020007014240A patent/KR20010052895A/ko not_active Withdrawn
- 1999-06-16 WO PCT/US1999/013623 patent/WO1999065491A1/en not_active Ceased
- 1999-06-16 EA EA200100041A patent/EA003584B1/ru not_active IP Right Cessation
- 1999-06-16 NZ NZ508532A patent/NZ508532A/en unknown
- 1999-06-16 AP APAP/P/2000/002002A patent/AP2000002002A0/en unknown
- 1999-06-16 BR BR9911150-0A patent/BR9911150A/pt not_active Application Discontinuation
- 1999-06-16 HU HU0102507A patent/HUP0102507A3/hu unknown
- 1999-06-16 CZ CZ20004698A patent/CZ20004698A3/cs unknown
- 1999-06-16 EP EP99930327A patent/EP1087766A4/en not_active Withdrawn
- 1999-06-16 CA CA002335236A patent/CA2335236A1/en not_active Abandoned
- 1999-06-16 AU AU46885/99A patent/AU740749B2/en not_active Ceased
- 1999-06-16 CN CN99807465A patent/CN1305379A/zh active Pending
- 1999-06-16 IL IL13994399A patent/IL139943A0/xx unknown
- 1999-06-16 PL PL99345261A patent/PL345261A1/xx not_active Application Discontinuation
- 1999-06-16 SK SK1919-2000A patent/SK19192000A3/sk unknown
-
2000
- 2000-12-12 ZA ZA200007396A patent/ZA200007396B/xx unknown
- 2000-12-14 NO NO20006383A patent/NO20006383L/no unknown
-
2001
- 2001-01-08 BG BG105127A patent/BG105127A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BG105127A (en) | 2001-11-30 |
| NZ508532A (en) | 2003-08-29 |
| EP1087766A4 (en) | 2001-11-21 |
| SK19192000A3 (sk) | 2001-05-10 |
| ZA200007396B (en) | 2002-02-27 |
| EP1087766A1 (en) | 2001-04-04 |
| HUP0102507A3 (en) | 2003-12-29 |
| EA200100041A1 (ru) | 2001-06-25 |
| JP2002518330A (ja) | 2002-06-25 |
| CZ20004698A3 (cs) | 2002-02-13 |
| CA2335236A1 (en) | 1999-12-23 |
| AU4688599A (en) | 2000-01-05 |
| PL345261A1 (en) | 2001-12-03 |
| NO20006383D0 (no) | 2000-12-14 |
| HUP0102507A2 (hu) | 2002-05-29 |
| AU740749B2 (en) | 2001-11-15 |
| GB9812941D0 (en) | 1998-08-12 |
| KR20010052895A (ko) | 2001-06-25 |
| IL139943A0 (en) | 2002-02-10 |
| NO20006383L (no) | 2000-12-14 |
| WO1999065491A1 (en) | 1999-12-23 |
| BR9911150A (pt) | 2001-03-06 |
| EA003584B1 (ru) | 2003-06-26 |
| CN1305379A (zh) | 2001-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL156122A0 (en) | Geldanamycin derivative and method of treating cancer using same | |
| AP1727A (en) | Methods and compositions for treating flaviviruses and pestiviruses. | |
| TW200505901A (en) | Muscarinic agonists | |
| DE60222137D1 (de) | Zuckerderivate von hydromorphon, dihydromorphin und dihydroisomorphin, zusammensetzungen davon und verwendung zur vorbeugung und behandlung von schmerzen | |
| NZ515567A (en) | Method for treating chronic pain using MEK inhibitors | |
| MXPA05003302A (es) | Compuestos de piperazina terapeuticos. | |
| PT998287E (pt) | Utilizacao de levobupivacaina | |
| IL182908A (en) | Method for the treatment of fibrosis using an antagonist of the integrin alpha-4 subunit | |
| TWI367751B (en) | Pharmaceutical composition comprising rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction | |
| MY118526A (en) | Method for improving the pharmacokinetics of tipranavir | |
| MY121623A (en) | Methods of preventing breast cancer. | |
| EP1262197A3 (en) | Combination treatment for sleep disorders including sleep apnea | |
| ZA984268B (en) | Method and composition for administering taxanes orally to human patients | |
| MY126321A (en) | Use of (alpha)-adrenoreceptor antagonists in the prevention and treatment of cancer. | |
| BG105127A (en) | Method for treament of nicotine addiction | |
| WO2002015894A3 (en) | Use of vitamin d derivatives as bone resorption inhibitors | |
| IL126158A0 (en) | Method for treating substance abuse | |
| WO2002007733A3 (en) | Method for enhancing bone mineral density gain by administration of raloxifene | |
| AU5434899A (en) | Cancer treatment | |
| IL141603A0 (en) | THE USE OF R(+)-α-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL) ETHYL] -4- PIPERIDINEMETHANOL FOR THE TREATMENT OF SLEEP DISORDERS | |
| AP2000001959A0 (en) | Treatment of generalized anxiety disorder with paroxetine. | |
| HK1080725A (en) | Pharmaceutical composition for treating pain comprising oxicarbazepine, or derivatives thereof, and cox2 inhibitors | |
| EA199800820A1 (ru) | Способ лечения злоупотребления лекарственными средствами |